Overview

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).
Phase:
Phase 2
Details
Lead Sponsor:
Angion Biomedica Corp
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)